Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl- benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion

Neuroscience

Volumn 90, Issue 1, 1999, Pages 79-85

  Degiorgio, L A ^a   Degiorgio, N ^a   Volpe, B T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Excitotoxicity; Glutamate receptor; MK 801; NBQX; Substantia nigra pars reticulata; Transneuronal degeneration

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; DIZOCILPINE; GLUTAMATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; GLOBUS PALLIDUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; GLOBUS PALLIDUS; IBOTENIC ACID; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PUTAMEN; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; SUBSTANTIA NIGRA;

EID: 0032977241     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00428-X     Document Type: Article

References (53)

1. Albin R.L., Makowiec R.L., Hollingsworth S.R., Dure L.S., Penney J.B., Young A.B. Excitatory amino binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48.
2. Bakker M.H.M., Foster A.C. An investigation of the mechanism of delayed neurodegeneration caused by the direct injection of quinolinate into the rat striatum in vivo. Neuroscience. 42:1991;387-395.
3. Balchen T., Diemer N.H. The AMPA antagonist, NBQX, protects against ischemia-induced loss of cerebellar Purkinje cells. NeuroReport. 3:1992;785-788.
4. Buchan A., Li H., Pulsinelli W.A. The N-methyl-D-aspartate antagonist, MK-801, fails to protect against neuronal damage caused by transient, severe forebrain ischemia in adult rats. J. Neurosci. 11:1991;1049-1056.
5. Buchan A., Pulsinelli W.A. Hypothermia but not the NMDA antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci. 10:1990;311-316.
6. Burke R.E., Macaya A., DeVivo D., Kenyon N., Janec E.M. Neonatal hypoxic ischemic or excitotoxic injury results in a decreased adult number of substantia nigra neurons. Neuroscience. 50:1992;559-569.
7. Coggeshall R., Lekan H.A. Method for determining numbers of cells and synapses: a case for more uniform standards of review. J. comp. Neuroanat. 364:1996;6-15.
8. Cowan W. M. (1970) Antero- and retrograde transneuronal degeneration in the central and peripheral nervous system. In Contemporary Research Methods in Neuroanatomy (eds Nauta W. H. J. and Ebbesson S.), pp. 217-251. Springer, New York.
9. DeGiorgio L.A., Dibinis C., Milner T.A., Saji M., Volpe B.T. Histological and temporal characteristics of nigral transneuronal degeneration after striatal injury. Brain Res. 759:1998;1-9.
10. DeGiorgio L.A., Volpe B.T. MK-801 prevents transneuronal degeneration of substantia nigra reticulata neurons following neurotoxic lesion of the striatum. Trans. Soc. Neurosci. 23:1997;2304.
11. Diemer N.H., Jorgensen M.B., Johansen F.F., Sheardown M., Honore T. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta neurol. scand. 86:1992;45-49.
12. Du C., Rong H., Csernansky C.A., Hsu C.Y., Choi D.W. Very delayed infarction after mild focal cerebral ischemia. J. cerebr. Blood Flow Metab. 16:1996;195-201.
13. Forno L.S. Reaction of the SN to massive basal ganglia infarction. Acta neuropath. 62:1983;96-102.
14. Forno L. S. (1990) Pathology of Parkinson's disease: the importance of the substantia nigra and Lewy bodies. In Parkinson's Disease (ed. Stern G.), p. 215. Johns Hopkins University Press, Baltimore, MD.
15. Foster A.C., Gill R., Woodruff G.N. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8:1988;4745-4754.
16. Gill R., Foster A., Woodruff G. MK-801 is neuroprotective in gerbils when administered during the post-ischemic period. Neuroscience. 25:1988;847-855.
17. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J. Pharmac. exp. Ther. 276:1996;1-4.
18. Hu P., Diemer N.H., Bruhn T., Johansen F.F. Effects of the AMPA-receptor antagonist, NBQX, on neuron loss in dentate hilus of the hippocampal formation after 8, 10, or 12 min of cerebral ischemia in the rat. J. cerebr. Blood Flow Metab. 17:1997;147-152.
19. Ishimaru H., Takahashi A., Ikarashi Y., Maruyama Y. Effects of MK-801 and pentobarbital on cholinergic terminal damage and delayed neuronal death in the ischemic gerbil hippocampus. Brain Res. Bull. 43:1997;81-85.
20. Judge M.E., Sheardown M.J., Jacobsen P., Honore T. Protection against post-ischemic behavioral pathology by the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) antagonist NBQX in the gerbil. Neurosci. Lett. 133:1991;291-294.
21. Kinouchi H., Sharp F.R., Chan P.H., Mikawa S., Kamii H., Arai S., Yoshimoto T. MK-801 inhibits the induction of immediate early genes in cerebral cortex, thalamus, and hippocampus, but not in substantia nigra following middle cerebral artery occlusion. Neurosci. Lett. 179:1994;111-114.
22. Krammer E.B. Anterograde and transynaptic degeneration 'en cascade' in basal ganglia induced by intrastriatal injection of kainic acid. Brain Res. 196:1980;209-221.
23. Macaya A., Munell F., Gubits R.M., Burke R.E. Apoptosis in substantia nigra following developmental striatal excitotoxic injury. Proc. natn. Acad. Sci. U.S.A. 91:1994;8117-8121.
24. Matini P., Moroni F., Lombardi G., Faussone-Pellegrini M.S., Moroni F. Ultrastructural and biochemical studies on the neuroprotective effects of excitatory amino acid antagonists in the ischemic rat retina. Expl Neurol. 146:1997;419-434.
25. Moncada C., Arvin B., Le Peillet E., Meldrum B.S. Non-NMDA antagonists protect against kainate more than AMPA toxicity in rat hippocampus. Neurosci. Lett. 133:1991;287-290.
26. Nakane M., Teraoka A., Asato R., Tamura A. Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke. 23:1992;328-332.
27. Nitsch R., Frotscher M. Reduction of posttraumatic transneuronal "early gene" activation and dendritic atrophy by the N-methyl-D-aspartate receptor antagonist MK-801. Proc. natn. Acad. Sci. U.S.A. 89:1992;5197-5200.
28. Olney J.W., Wozniak D.F., Farber N.B. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Archs Neurol. 54:1997;1234-1240.
29. Oo T.F., Henchcliffe C., Burke R.E. Apoptosis in substantia nigra following developmental hypoxic-ischemic injury. Neuroscience. 69:1995;893-901.
30. Pasinetti G.M., Morgan D.G., Finch C.E. Disappearance of GAD mRNA and tyrosine hydroxylase in substantia nigra following striatal ibotenic acid lesions. Expl Neurol. 112:1991;131-139.
31. Price R.H., Hollingsworth Z., Young A.B., Penney J.B. Excitatory amino acid receptor regulation after subthalamic nucleus lesion in the rat. Brain Res. 602:1993;157-160.
32. Quarrell O. (1991) The neurobiology of Huntington's disease. In Huntington's Disease (ed. Harper P. S.), Vol. 22, pp. 141-78. Saunders, New York.
33. Rosenthal R. L. and Rosnow D. B. (1985) Contrast Analysis: Comparisons in the Analysis of Variance. Cambridge University Press, Cambridge.
34. Ross D.T., Ebner F.F. Thalamic retrograde degeneration following cortical injury: an excitotoxic process? Neuroscience. 35:1990;525-550.
35. Saji M., Reis D.J. Delayed transneuronal death of SN neurons prevented by GABA antagonist. Science. 235:1986;66-68.
36. Saji M., Volpe B.T. Delayed histologic damage and neuron death in the substantia nigra reticulata following transient forebrain ischemia depends on the extent of initial striatal injury. Neurosci. Lett. 155:1993;47-50.
37. Saji M., Cohen M., Blau A.D., Wessel T.C., Volpe B.T. Transient forebrain ischemia induces delayed injury in the substantia nigra reticulata: degeneration of GABA neurons, compensatory expression of GAD mRNA. Brain Res. 643:1994;234-244.
38. Saji M., Kimura M., Ishida G., Ohno G. Deafferentiation-induced c-fos gene expression in subthalamic nucleus and substantia nigra reticulata is reduced by non-NMDA receptor antagonist. Brain Res. 703:1995;165-174.
39. Saji M., Blau A.D., Volpe B.T. Prevention of transneuronal degeneration in the substantia nigra reticulata by ablation of the subthalamic nucleus. Expl Neurol. 141:1996;120-129.
40. Saji M., Endo Y., Miyanishi T., Volpe B.T., Ohno K. Movement disorders after substantia nigra reticulata transneuronal degeneration and rescue. Behav. Brain Res. 84:1997;63-71.
41. Schallert T., Lindner M.D. Rescuing neurons from trans-synaptic degeneration after brain damage: helpful, harmful, or neutral in recovery of function? Can. J. Psychol. 44:1990;276-292.
42. Shan Y., Carlock L.R., Walker P.D. NMDA receptor overstimulation triggers a prolonged wave of immediate early gene expression: relationship to excitotoxicity. Expl Neurol. 144:1997;406-415.
43. Sheardown M.J., Suzdak P.D., Nordholm L. AMPA, but not NMDA receptor antagonism is neuroprotective in gerbil global ischemia even when delayed 24 hours. Eur. J. Pharmac. 236:1993;347-353.
44. Stefanis L., Burke R.E. Transneuronal degeneration in substantia nigra pars reticulata following striatal excitotoxic injury in adult rat: time-course, distribution, and morphology of cell death. Neuroscience. 74:1996;997-1008.
45. Stuiver B.T., Douma B.R., Bakker R., Nyakas C., Luiten P.G. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration. 5:1996;153-159.
46. Tamura A., Kirino T., Sano K., Takagi K., Oka H. Atrophy of ipsilateral substantia nigra following middle cerebral artery occlusion in the rat. Brain Res. 510:1990;154-157.
47. Volpe B.T., Saji M. Rescue of neurons from the SNR from transneuronal degeneration by ablation of the subthalamic nucleus. Neurology. 45:1995;530.
48. Volpe B.T., Blau A.D., Wessel T.C., Saji M. Delayed histopathological neuronal damage in the substantia nigra compacta (nucleus A9) after transient forebrain ischemia. Neurobiol. Dis. 2:1995;119-127.
49. Volpe B.T., Wildmann J., Altar C.A. Brain derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience. 83:1998;741-748.
50. Wong E., Kemp J., Priestly T., Knight A., Woodruff G., Iversen L. The anticonvulsant MK-801 is a potent NMDA antagonist. Proc. natn. Acad. Sci. U.S.A. 83:1986;7104-7108.
51. Yamada K., Goto S., Yoshikawa M., Okamura A., Ushio Y. Involvement of N-methyl-D-aspartate receptor in the delayed transneuronal regression of substantia nigra neurons in rats. Brain Res. 743:1996;233-239.
52. Yamada K., Goto S., Yoshikawa M., Okamura A., Ushio Y. Continuous intraventricular drug infusion for the in vivo study of transneuronal degeneration in the striatonigral system of the rat. Brain Res. Brain Res. Protoc. 1:1997;371-377.
53. Young A.B., Fagg G.E. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic procedures. Trends pharmac. Sci. 11:1990;126-133.